Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilta-cel versus PVd or DPd in relapsed, lenalidomide-refractory multiple myeloma
jRCT1080225184Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
01
Overview
Phase 3, randomised trial of ciltacabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Started May 2020; status: completed.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT1080225184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080225184.